GoodRx Holdings (GDRX) Research & Development (2019 - 2026)
GoodRx Holdings' Research & Development history spans 7 years, with the latest figure at $28.9 million for Q4 2025.
- On a quarterly basis, Research & Development fell 8.82% to $28.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $121.0 million, a 2.2% decrease, with the full-year FY2025 number at $121.0 million, down 2.2% from a year prior.
- Research & Development hit $28.9 million in Q4 2025 for GoodRx Holdings, down from $31.0 million in the prior quarter.
- Over the last five years, Research & Development for GDRX hit a ceiling of $39.6 million in Q3 2023 and a floor of $26.2 million in Q1 2021.
- Historically, Research & Development has averaged $32.5 million across 5 years, with a median of $31.5 million in 2023.
- Biggest five-year swings in Research & Development: skyrocketed 153.37% in 2021 and later fell 23.91% in 2024.
- Tracing GDRX's Research & Development over 5 years: stood at $35.1 million in 2021, then grew by 4.88% to $36.8 million in 2022, then decreased by 12.89% to $32.0 million in 2023, then dropped by 0.91% to $31.7 million in 2024, then decreased by 8.82% to $28.9 million in 2025.
- Business Quant data shows Research & Development for GDRX at $28.9 million in Q4 2025, $31.0 million in Q3 2025, and $29.9 million in Q2 2025.